BI
MRSN

BVF Inc’s Mersana Therapeutics MRSN Stock Holding History

BVF Inc’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-94,896
Closed -$13.8M – 62
2020
Q1 		$13.8M Buy
94,896
+47,674
+101% +$8.33M 1.29% 24
2019
Q4 		$6.76M Sell
47,222
-114,454
-71% -$8.37M 0.51% 37
2019
Q3 		$6.39M Buy
161,676
+61,760
+62% +$4.49M 0.67% 39
2019
Q2 		$10.1M Sell
99,916
-84
-0.1% -$9.89K 1.1% 29
2019
Q1 		$13.2M Buy
+100,000
New +$12.6M 1.47% 24

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BVF Inc's MRSN Position: Q2 2020 in Review

BVF Inc sold out of Mersana Therapeutics (MRSN) in Q2 2020, closing a stake of 94,896 shares — an estimated $13.8M sold.

BVF Inc first reported a position in MRSN in Q1 2019 and held it in 5 quarters. The position peaked at $13.8M in Q1 2020. 130 funds tracked by Wall St. Rank hold MRSN as of Q2 2020.

  • BVF Inc reported no remaining Mersana Therapeutics position as of Q2 2020 after selling out during the quarter.
  • BVF Inc sold 94,896 Mersana Therapeutics shares in Q2 2020, an estimated $13.8M.
  • BVF Inc first reported a position in Mersana Therapeutics in Q1 2019 and held it in 5 quarters.
  • BVF Inc's Mersana Therapeutics position peaked at $13.8M in Q1 2020.
  • 130 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2020.

Based on BVF Inc's 13F filing for Q2 2020, filed 14 Aug 2020.